TYK Medicines-B (02410) climbed more than 9% in early trading, with shares up 9.17% at HK$4.23 as of press time, on turnover of HK$2.28361 million.
TYK Medicines-B announced that, as previously disclosed on August 27, 2026, its independently developed new drug Cardasha (TY-9591) has received conditional marketing approval from China's National Medical Products Administration for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) exon 19 deletion (19DEL) or exon 21 (L858R) substitution mutations and accompanying central nervous system (CNS) metastases.
The first batch of Cardasha (TY-9591) is expected to complete production on November 18, 2026. By late November 2026, the first batch of Cardasha (TY-9591) products is expected to be officially shipped through commercial channels to Qilu's designated first-tier distributors. Qilu is expected to launch academic promotion activities on November 13, 2026, marking the official commencement of commercial sales and prescription business for Cardasha (TY-9591) in China.
Looking ahead, the company will continue to collaborate with Qilu Pharmaceutical (Hainan) Co., Ltd. (Qilu) to commercialize Cardasha (TY-9591) in accordance with the licensing and cooperation agreement and the supply and commercialization agreement outlined in the company's announcements dated July 21, 2026 and November 11, 2026.
Comments